23026

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

·	Under the Paperwork Reduction Act of 1995, no persons are required to					<u> </u>			
S	UTILITY	Att	tomey Docker	ı IVU.	PC10203C				
). PT0	PATENT APPLICATION	First Inventor			Jotham Wadsworth Coe				
O'	TRANSMITTAL	Title			ARYL FUSED AZAPOLYCYCLIC COMPOUNDS				
(Only f	r new nonapplications under 37C.F.R. §1.53(b))	Express Mail Label No.			EL 874867	934 US			
	APPLICATION ELEMENTS PEP chapter 600 concerning utility patent application contents.		Mail Stop <u>Patent Application</u> Commissioner for Patents Box 1450 Alexandria, VA 22313-1450						
1. 2. 3	Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)  Applicant claims small entity status See 37 CFR 1.27  Specification [Total Pages 75] (preferred arrangement set forth below)  Descriptive title of the Invention Cross References to Related Applications Statement Regarding Fed sponsored R&D Reference to sequence listing, a table, or a computer program listing appendix Background of the Invention Brief Summary of the Invention Brief Description of the Drawings (if filed) Detailed Description Claim(s) Abstract of the Disclosure  Drawing(s) (35 U.S.C. 113) [Total sheets  Newly executed (original or copy) b. Copy from a prior application (37 CFR §1.63(d)) (for continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).  Application Data Sheet. See 37 CFR 1.76	7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17.  17.  17.  17.  17.  17.  17.	cor Nucleotid (if applica  a.   b. Sp  i.  c.   ACC  Ass  ASS  ASS  ASS  C.   Infe  Sta  B.  Re  (SI  C.   Company  Comp	mputer Progress and/or Art able, all nec and/or Art able and and/or Art able	D-R in dupling am (Appennino Acid Seessary)  uter Readab  Sequence L  OM or CD-R  ment verifying  YING APPI  apers (cover  Statement an assigned lation Docum sclosure S)/PTO-144  mendment of Postcard ( ecifically iter of Priority E rity is claime in Request un pplicant mus int.	cate, large table or dix) equence Submission  le Copy (CRF) isting on: (2 copies)  g identity of above copies  LICATION PARTS  sheet & document(s))  Power of Attorr  e) nent (if applicable) Copies of IDS Citations  MPEP 503) mized) cocument(s) d) nder 35 U.S.C. 122 t attach form PTO/SB/35	se 031356 U.S. PTO		
	or in an Application Data Sheet under 3/CFR 1.76.  Continuation Divisional Continuation-in-part (CIP) of prior application No. 10/217,771  Prior application information: Examiner Patel Group/Art Unit: 1624								
For CONTINUATION OR DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.  The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts  CORDESCONDENCE ADDRESC									
<u> </u>	19. CORRESPONDENCE ADDRESS								
	Customer Number 23913 or Correspondence address below								
Name	9								
Addr	ess								
City	State	$oldsymbol{\bot}$			Zip Code				
Cour	ntry Telephøne	$\bot$			Fax				
	NAME (Print/type) A. David/Joran	Re	gistration No	o. (Attorney/	(Agent)	37,858			
	Signature / DW/	7		Date	30 CAC	January 23, 2004			

This collection of information is required by 37 U.S.C. 122 and 37 CFR1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending/upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you leed assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office;U.S. DEPARTMENT OFCOMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FFF TDANORATTAL						Complete if Known							
FEE TRANSMITTAL						Application Number Not yet assigned							
for FY 2004							Filing Date Concurrently herewith						
							First Named Inventor Jotham Wadsworth Coe						
Effective 10/01/2003. Patent fees are subject to annual revision.						Examiner Name Patel S.							
				. See 37 CFR 1.27		Art Unit 1624							
Total Am	ount	of Payr	ment	\$770.00		PC ; PC10203C							
			AYME	NT (check all tha	it apply)	FEE CALCULATION (continued)							
☐ Check ☐ Credit Card ☐ Money ☐ Other ☐ None Order					3. ADDITIONAL FEES Large Entity Small Entity								
□ Deposit Account:     □					Fee Code	Fee (\$)	Fee Code	Fee (\$)	1			Fee Paid	
Deposit Account 16-1445				1051	130	2051	65	Surcharge	- late fee or oath				
Number Deposit	F	Pfizer Ir	nc			1052	50	2052	25	Surcharge-late filing fee or cover sheet			
Account Name		uth oriz	ad to : /	check all that appl	<u></u>	1053	130	1053	130	, Non-Englis			
				Credit any of contract of fe		1812 1804	2,520 920*	1812 1804	2,520 920*	For filing a request for Ex Parte reexamination Requesting publication of SIR prior to			
Charge to the above				cept for the filing fe	e	1805	1,840*	1805	1,840*	Examiner action Requesting publication of SIR after Examiner action			
to the above	3-106111111			CULATION		1251	110	2251	55	Extension for reply within first month			
1. BASIC	FILIN	IG FEE				1252	420	2252	210	Extension	for reply within second	month	
Large En	ntity	Small	Entity	<u>_</u>		1253	950	2253	475	1	for reply within third		
	ee	Fee Code	Fee			1254	1,480	2254	740	Extension	for reply within fourt	th month	
Çode (\$			(\$)	Fee Description	Fee Paid	1255	2,010	2255	1,005	1 Extension	for reply within fifth	month	
	70	2001	385	Utility filing fee	770	1401	330	2401	165	Notice of		monai	
	40 30	2002 2203	170 265	Design filing fee Plant filing fee		1401	330	2401	165		ief in support of an a	ppeal	
	70	2004	385	Reissue filing fee		1403	290	2403	145	Request for	or oral hearing		
1005 16	60	2005	80	filing fee		1451	1,510	1451	1,510	Petition to	institute a public use pro	ceeding	
	•					1452	110	2452	55	Petition to	revive unavoidable		
			Subto	otal (1)s	\$ 770	1453	1,330	2453	665	Petition to	revive - unintention	al	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE						1501	1,330	2501	665	Utility issu	e fee (or reissue)		
Extra Claims Fee from Fee Pald						1502	480	2502	240	Design iss	sue fee		
Total Claims 14 - 20** = 0 x 18 = 0					= 0	1503	503 640 2503 3		320	Plant issue fee			<u> </u>
Independent 1 -3 = 0 x 86 = 0					= 0	1460	130	1460	130	Petitions t	o the Commissioner	•	
Claims						1807	50	1807	50	Processin	g fee under 37 CFR	1 17(a)	
Multiple Dependent = 0						1806	180	1806	180	)	on of Information Disclos		
Large Entit	v	Small Er	ntitv										
Fee Fe	ee	Fee	Fee	Fee Description		8021	40	8021	40		each patent assign		
Code (\$	18	Code 2202	( <b>\$</b> )	Claims in excess of	20	1809	770	2809	385	property (times number of properties) Filing a submission after final rejection			
1201	86	2201	43	Independent claims	n excess of 3	1810	770	2810	385	(37 CFR 1.129(a)) For each additional invention to be			
1203	290	2203	145	Multiple dependent of	laim, if not paid	1801	770	2801	385	examined (37 CFR 1.129(b)) Request for Continued Examination (RCE)			
1204	86	2204	43	**Reissue independe	ent claims over original patent	1802	900	1802	900	Request for expedited examination of a design application			
1205 18 2205 9 **Reissue independent claims over original patent					Other Fee (specify)								
(\$) 0													
			aid, if gre	eater; For Reissues,	see apove	*Reduc	ed by Basic	Filing F			f applicable)	(\$)	
SUBMITTED BY  Name (Printed/Type) A. David Jofan					Regis	tration No	37	858	omplete l	f applicable)  Telephone	212-733-	3381	
Starry						ney Agent				2.0,2			
Signature	,				11/- //								

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37, CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file ( and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and /or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-pto-9199 and select option2.

IN THE UNITED STATES PATENT AND	D TRADEMARK OFFICE
IN RE APPLICATION OF: Jotham Wadsworth Coe	: Examiner: PATEL, S. B.
APPLICATION NO.: Not Yet Assigned	: . Group Art Unit: 1624
FILING DATE: Concurrently Herewith	
TITLE: ARYL FUSED AZAPOLYCYCLIC COMPOUNDS	:
Commissioner for Patents Box Patent Application P.O. Box 1450 Alexandria, VA. 22313-1450	
Sir:	
CERTIFICATE UNDER 37	CFR §3.73(B)
Pfizer Inc , a	Corporation of the State of Delaware
(Name of Assignee)	(Type of Assignee, e.g. corporation, partnership, university, government agency, etc.)
certifies that it is the assignee of the entire right, title aridentified above by virtue of either:	nd interest in the patent application
A. [X] An assignment from the inventor(s) of	of the patent application identified
above. The assignment was recorded in the Pater	nt and Trademark Office at Reel
012975, Frame 0297, or for which a copy thereof is	s attached.
OR	
B. [ ] A chain of title from the inventor(s), of the current assignee as shown below:	e patent application identified above, to
1. From: To:	
The document was recorded in the Patent and Tra	
Reel, Frame, or for which a copy thereof is	attached.
2. From: To:	

The document was recorded in the Patent and Trademark Office at

Attorney Docket No. PC10203C

3.	3. From: To:	
	The document was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.	
	[] Additional documents in the chain of title are listed on a supplemental sh	ieet.
	[] Copies of assignments or other documents in the chain of title are attach	ned.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

January 23, 2004 Date

Bv:

A. David Joran
Patent Attorney

Pfizer Inc

Reg. No. 37,858